



Health
Canada Santé
Canada

Your health and
safety... our priority.

Votre santé et votre
sécurité... notre priorité.

ERC2007-09

Evaluation Report

Ammonium Bromide Fuzzicide

(publié aussi en français)

13 November 2007

This document is published by the Health Canada Pest Management Regulatory Agency. For further information, please contact:

Publications
Pest Management Regulatory Agency
Health Canada
2720 Riverside Drive
A.L. 6605C
Ottawa, Ontario
K1A 0K9

Internet: pmra_publications@hc-sc.gc.ca
www.pmra-arla.gc.ca
Facsimile: 613-736-3758
Information Service:
1-800-267-6315 or 613-736-3799
pmra_infoserv@hc-sc.gc.ca

Canada 

ISBN: 978-0-662-47254-4 (978-0-662-47255-1)
Catalogue number: H113-26/2007-9E (H113-26/2007-9E-PDF)

© Her Majesty the Queen in Right of Canada, represented by the Minister of Health Canada, 2007

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of the Minister of Public Works and Government Services Canada, Ottawa, Ontario K1A 0S5.

Table of Contents

Overview	1
Registration Decision for Ammonium Bromide	1
What Does Health Canada Consider When Making a Registration Decision?	1
What Is Fuzzicide?	2
Health Considerations	2
Environmental Considerations	4
Value Considerations	4
Measures to Minimize Risk	4
What Additional Scientific Information Is Required?	5
Other Information	5
Science Evaluation	6
1.0 The Technical Grade Active Ingredient, its Properties and Uses	6
1.1 Identity of the Technical Grade Active Ingredient	6
1.2 Physical and Chemical Properties of the Active Ingredient and End-Use Product	6
1.3 Directions for Use	8
1.4 Mode of Action	8
2.0 Methods of Analysis	8
2.1 Methods for Analysis of the Technical Grade of Active Ingredient	8
2.2 Method for Formulation Analysis	8
2.3 Methods for Residue Analysis	8
3.0 Impact on Human and Animal Health	9
3.1 Toxicology Summary	9
3.2 Determination of Acceptable Daily Intake	12
3.3 Determination of Acute Reference Dose	12
3.4 Occupational and Bystander Risk Assessment	12
3.4.1 Toxicological Endpoints	12
3.4.2 Occupational Exposure and Risk	12
3.4.3 Residential Exposure and Risk	13
3.4.4 Bystander Exposure and Risk Assessment	13
4.0 Impact on the Environment	13
4.1 Fate and Behaviour in the Environment	13
4.2 Effects on Non-Target Species	14
4.2.1 Effects on Terrestrial Organisms	14
4.2.2 Effects on Aquatic Organisms	14

5.0	Value	15
5.1	Effectiveness Against Pests	15
5.1.1	Acceptable Efficacy Claims	15
5.2	Sustainability	16
5.2.1	Survey of Alternatives	16
5.2.2	Compatibility with Current Management Practices Including Integrated Pest Management	16
5.2.3	Information on the Occurrence or Possible Occurrence of the Development of Resistance	16
6.0	Toxic Substances Management Policy Considerations	16
7.0	Summary	17
7.1	Human Health and Safety	17
7.2	Environmental Risk	18
7.3	Value	18
8.0	Regulatory Decision	18
	List of Abbreviations	20
	Appendix I Tables and Figures	21
	Table 1 Acute Toxicity of Ammonium Bromide Technical and Its Associated End-use Product (Fuzzicide Solution)	21
	Table 2 Toxicity Profile of Ammonium Bromide Technical	22
	Table 3 Toxicity Studies Conducted with Sodium Bromide	23
	Table 4 Toxicity Studies Conducted with Ammonia	24
	Table 5 Fate and Behaviour in the Environment	25
	Table 6 Effects on Terrestrial and Aquatic Organisms	26
	Table 7 Alternative Slimicides for Pulp and Paper Mill Use	28
	Table 8 Unsupported Proposed Use (label) Claims	30
	List of References	32

Overview

Registration Decision for Ammonium Bromide

Health Canada's Pest Management Regulatory Agency (PMRA), under the authority of the [Pest Control Products Act](#) and in accordance with the Pest Control Products Regulations, has granted conditional registration for the sale and use of Fuzzicide (Ammonium Bromide) and the end-use product Fuzzicide Solution (35% solution of ammonium bromide), both containing the active ingredient ammonium bromide.

Current scientific data from the applicant and relevant scientific reports were evaluated to determine if, under the proposed conditions of use, ammonium bromide has value and does not present an unacceptable risk to human health or the environment.

This report summarizes the information evaluated and provides the results of the evaluation as well as the reasons for the conditional registration, with an outline of the additional scientific information required from the applicant. It also describes the conditions of registration that the applicant must meet to ensure that the health and environmental risks as well as the value of these pest control products are acceptable for their intended use.

This Overview describes the key points of the evaluation, while the Science Evaluation section provides detailed technical information on the human health, environmental and value assessments of Fuzzicide (Ammonium Bromide) and the end-use product Fuzzicide Solution.

What Does Health Canada Consider When Making a Registration Decision?

The key objective of the *Pest Control Products Act* is to prevent unacceptable risks¹ to people and the environment from the use of pest control products. Health or environmental risk is considered acceptable if there is reasonable certainty that no harm to human health, future generations or the environment will result from use or exposure to the product under its conditions or proposed conditions of registration. The Act also requires that products have value² when used according to the label directions. Conditions of registration may include special precautionary measures on the product label to further reduce risk.

To reach its decisions, the PMRA applies modern, rigorous risk-assessment methods and policies. These methods consider the unique characteristics of sensitive subpopulations in humans (e.g. children) as well as organisms in the environment (e.g. those most sensitive to environmental contaminants). These methods and policies also consider the nature of the effects

¹ "Acceptable risks" as defined by subsection 2(2) of the *Pest Control Products Act*.

² "Value" as defined by subsection 2(1) of the *Pest Control Products Act* "...the product's actual or potential contribution to pest management, taking into account its conditions or proposed conditions of registration, and includes the product's (a) efficacy; (b) effect on host organisms in connection with which it is intended to be used; and (c) health, safety and environmental benefits and social and economic impact".

observed and the uncertainties present when predicting the impact of pesticides. For more information on how the PMRA regulates pesticides, the assessment process and risk-reduction programs, please visit the PMRA's website at www.pmra-arla.gc.ca.

What Is Fuzzicide?

The technical product Fuzzicide consists of 99% ammonium bromide, while the end-use product Fuzzicide Solution is a 35% solution of ammonium bromide. The end-use product is used as a slimicide³ in pulp and paper mill whitewater systems and starch slurries. Fuzzicide Solution is used with sodium hypochlorite to produce the active biocide⁴ (Fuzzicide biocide).

Health Considerations

Can Approved Uses of Ammonium Bromide Affect Human Health?

Ammonium bromide is unlikely to affect your health when used according to the label directions.

When assessing health risks, the PMRA considers two key factors: the levels where no health effects occur and the levels to which people may be exposed. The dose levels used to assess risks are established to protect the most sensitive human population (e.g. children and nursing mothers). The risk assessment is conducted to ensure that the level of human exposure is well below the lowest dose at which effects occurred in animal tests. Only uses for which the exposure is well below levels that cause no effects in animal testing are considered acceptable for registration.

Toxicology studies in laboratory animals describe potential health effects from varying levels of exposure to a chemical and identify the dose at which no effects are observed. All of the toxicology studies routinely required to register a pesticide were not available for ammonium bromide. However, because exposure was determined to be negligible for the proposed use on pulp and paper, no further studies were requested. For any future use expansions, however, the PMRA will reconsider the need to address data gaps.

The technical grade active ingredient ammonium bromide caused mild eye irritation in animals and showed the potential to cause acute health effects in animals when it was inhaled. Consequently, the statements "Caution—Eye Irritant" and "Warning—Poison" are required on the label as well as the skull and crossbones symbol. Health effects in animals given daily doses of ammonium bromide over short periods (4 weeks to 3 months) included clinical signs of toxicity, decreased body- and organ-weights as well as effects on blood and urine. Although ammonium bromide was not tested to see if it

³ Chemical added to the pulp and paper process to inhibit the growth of undesirable microorganisms that cause slime.

⁴ This active biocide prevents the presence of undesirable organisms.

causes cancer, it was not found to be genotoxic⁵. Ammonia on its own, however, has been found to cause some forms of genotoxicity. Some effects were noted on the nervous system, including clinical signs of toxicity, behavioural effects and some indications of effects on nervous tissue. When ammonium bromide was given to pregnant animals, effects on the developing fetus and on offspring were observed at doses that were not toxic to the mother, indicating that the fetus or young animal was more sensitive to ammonium bromide than the adult animal. Effects on reproduction were also seen, but at doses that were toxic to adult animals.

Studies conducted with sodium bromide were also provided to supplement the ammonium bromide toxicology database. When given to pregnant animals, sodium bromide caused effects on offspring at doses that were also toxic to the mother. Effects on reproduction were seen at doses that were toxic to adult animals. Other effects on adult animals included decreased thyroid-hormone levels, decreased body weights and organ weights as well as effects on blood at very high doses.

Occupational Risks From Handling Ammonium Bromide

Occupational risks are not of concern when ammonium bromide is used according to the label directions, which include protective measures.

Due to the requirement for closed loading and transfer of Fuzzicide Solution, workers mixing and loading the product are not expected to have direct contact with ammonium bromide. In addition, the label will specify that anyone mixing or loading Fuzzicide Solution must wear face protection, a long-sleeved shirt and long pants, chemical-resistant gloves and chemical-resistant footwear. Taking into consideration these label requirements, risk to workers handling Fuzzicide Solution is not of concern.

Postapplication exposure of workers to treated process water in pulp and paper mills is considered negligible when the recommended personal protective equipment is worn and is, therefore, not of concern.

Risks in Non-Occupational Environments

Estimated risk for non-occupational exposure is not of concern when directions specified on the label are observed.

Exposure to individuals contacting treated paper is not expected to result in unacceptable risk when Fuzzicide Solution is used according to the label directions.

For bystanders, exposure is expected to be much less than that of workers and is considered negligible.

⁵ Genotoxic chemicals are those capable of causing damage to DNA. Such damage can potentially lead to the formation of a malignant tumour, but DNA damage does not lead inevitably to the creation of cancerous cells.

Environmental Considerations

What Happens When Fuzzicide Biocide is Introduced Into the Environment?

Fuzzicide biocide is toxic to freshwater alga and vascular plants and to both freshwater and marine invertebrates and fish; therefore, label instructions are required to protect these organisms and to minimize exposure to the aquatic environment.

Fuzzicide Solution has to be reacted with a 12.5% aqueous solution of sodium hypochlorite to form the active biocide, Fuzzicide biocide or bromide-activated chloramine (BAC). Fuzzicide biocide has the potential to enter into the environment when used as a slimicide in pulp and paper mills. This active biocide is not persistent in the aquatic system and is rapidly degraded to substances such as ammonia/ammonium, nitrate, chloride, bromide, bromoform and chloroform which are already found in natural and effluent waters. With the exception of ammonium, the transformation products of BAC are not expected to adsorb to sediment. Under actual use conditions in an operational pulp and paper mill, Fuzzicide biocide concentrations were below the detection limit (0.05 mg Cl₂/L) at the point of discharge into the watercourse. Soil is not expected to be exposed to Fuzzicide residues; therefore, these residues are not expected to be found in the terrestrial environment.

Based on the specific use pattern for Fuzzicide Solution in pulp and paper mills, Fuzzicide biocide presents a negligible risk to aquatic organisms. Specific statements regarding its toxicity to aquatic organisms and statements to minimize exposure to the aquatic environment are provided on the product label.

Value Considerations

What Is the Value of Fuzzicide Solution?

Fuzzicide Solution is a slimicide for use in pulp and paper mill whitewater systems and starch slurries. Fuzzicide Solution is used with sodium hypochlorite (12.5%) via the Fuzzicide feeder/delivery system to produce Fuzzicide biocide. This product is a new alternative slimicide that can be used to prevent the fouling of whitewater systems and starch slurries caused by bacterial, fungal and algal contamination that have been known to result in loss of productivity in pulp and paper mills.

Measures to Minimize Risk

Labels of registered pesticide products include specific instructions for use. Directions include risk-reduction measures to protect human and environmental health. These directions must be followed by law. The PMRA is requiring key risk-reduction measures on the label of Fuzzicide Solution.

Human Health

- To avoid direct contact with ammonium bromide on the skin, only closed loading and transfer is permitted for Fuzzicide Solution. In addition, anyone handling Fuzzicide Solution or contacting treated process fluids must wear face protection, a long-sleeved shirt and long pants, chemical-resistant gloves and chemical-resistant footwear.

Environment

- Fuzzicide biocide is toxic to freshwater alga, vascular plants, freshwater and marine invertebrates as well as to fish; therefore, specific statements to minimize exposure to the aquatic environment are provided on the product label.

What Additional Scientific Information Is Required?

Although the risks and value have been found acceptable when all risk-reduction measures are followed, the applicant must submit additional scientific information as a condition of registration. More details are presented in the Science Evaluation section of this report or in the Section 12 Notice associated with these conditional registrations. The applicant must submit the following information within the time frames indicated.

- **Environment**

A hydrolysis study conducted with the Fuzzicide biocide, the bromide-activated chloramine, in sterile water at 3 different pHs (e.g. pH 4.0, pH 7.0 and pH 9.0) is required. This study is to be submitted to the PMRA by 1 September 2009.

Other Information

As these conditional registrations relate to a decision on which the public must be consulted⁶, the PMRA will publish a consultation document when there is a proposed decision on the applications to convert the conditional registrations to full registrations or on the applications to renew the conditional registrations, whichever occurs first.

The test data cited in this Evaluation Report (i.e. the test data relevant in supporting the registration decision) will be made available for public inspection when the decision is made to convert the conditional registrations to full registrations or to renew the conditional registrations (following public consultation). If more information is required, please contact the PMRA's Pest Management Information Service by phone (1-800-267-6315) or by e-mail (pmra_infoserv@hc-sc.gc.ca).

⁶ As per subsection 28(1) of the *Pest Control Products Act*.

Science Evaluation

Fuzzicide (Ammonium Bromide)

1.0 The Technical Grade Active Ingredient, its Properties and Uses

1.1 Identity of the Technical Grade Active Ingredient

Active substance	ammonium bromide
Function	antimicrobial
Chemical name	
1. International Union of Pure and Applied Chemistry (IUPAC)	ammonium bromide
2. Chemical Abstracts Service (CAS)	ammonium bromide
CAS number	12124-97-9
Molecular formula	BrH ₄ N
Molecular weight	97.94
Structural formula	NH ₄ ⁺ Br
Purity of the active ingredient	99% nominal

1.2 Physical and Chemical Properties of the Active Ingredient and End-Use Product

Technical Product—Fuzzicide (Ammonium Bromide) Technical

Property	Result
Colour and physical state	White powder
Odour	Odourless
Melting point	>370°C
Boiling point	N/A
Density	2.4550 g/mL
Vapour pressure at 25°C	1.3 × 10 ⁻⁴ Pa

Property	Result										
Henry's law constant at 20°C	1.3×10^{-10} atm·m ³ /mol										
Ultraviolet (UV)—visible spectrum	Not expected to absorb at $\lambda > 300$ nm										
Solubility in water at 25°C	97 g/100 mL										
Solubility in organic solvents	<table border="1"> <thead> <tr> <th>Solvent</th> <th>Solubility</th> </tr> </thead> <tbody> <tr> <td>alcohol</td> <td>10 g/100 cm³ at 78°C</td> </tr> <tr> <td>acetone</td> <td>soluble</td> </tr> <tr> <td>ether</td> <td>soluble</td> </tr> <tr> <td>ammonia</td> <td>soluble</td> </tr> </tbody> </table>	Solvent	Solubility	alcohol	10 g/100 cm ³ at 78°C	acetone	soluble	ether	soluble	ammonia	soluble
Solvent	Solubility										
alcohol	10 g/100 cm ³ at 78°C										
acetone	soluble										
ether	soluble										
ammonia	soluble										
<i>n</i> -Octanol–water partition coefficient (K_{ow})	N/A										
Dissociation constant (pK_a)	N/A										
Stability (temperature, metal)	Stable to sunlight and elevated temperature; stable to metals when pure substances are used, but may corrode metals after exposure to moisture										

End-Use Product—Fuzzicide Solution (35% Ammonium Bromide)

Property	Result
Colour	Colourless
Odour	Weak ammonia
Physical state	Liquid
Formulation type	Solution
Guarantee	35% nominal
Container material and description	HDPE intermediate bulk containers (1000 L) and drums (210 L)
Specific gravity at 20°C	1.22–1.24
pH	6.5–6.8
Oxidizing or reducing action	No significant oxidizing or reducing action
Storage stability	Stable over 24 months at ambient conditions
Explosibility	Not known to be explosive

1.3 Directions for Use

Fuzzicide Solution is used in conjunction with sodium hypochlorite (12.5%) in the Fuzzicide feeder/delivery system to produce the active biocide. Mixing is carried out at a ratio of 2.2 litres of sodium hypochlorite (12.5%) with 1.0 L of Fuzzicide Solution in the feeder, to control algal, bacterial and fungal slimes in pulp and paper mill whitewater systems and starch slurries. The relevant parameters for treatment (Table 1.3.1) are supported by data.

Table 1.3.1 Microbial Slime Control Claims for Fuzzicide Solution in Pulp and Paper Mills

Site	Residual biocide to be maintained, expressed as total chlorine
Whitewater Systems	0.5–5.0 ppm
Starch Slurries	up to 10.0 ppm

1.4 Mode of Action

The Fuzzicide biocide resulting from the reaction between chlorine and ammonium bromide, affects protein-associated processes in bacteria by reacting with multiple targets including amino acids, particularly tryptophan and those with sulfur groups. In addition the biocide inhibits nucleic acid (DNA and RNA) and protein synthesis and inhibits bacterial growth.

Furthermore, the Fuzzicide biocide is an oxidizing biocide that is less reactive than chlorine (hypochlorous acid). Therefore, it is not consumed as rapidly by organic compounds in the pulp and paper process and is available to react with strong reducing groups present on the cell membrane or within the cytoplasm of microorganisms.

2.0 Methods of Analysis

2.1 Methods for Analysis of the Technical Grade of Active Ingredient

The methods provided for the analysis of the active ingredient and the impurities in Fuzzicide (ammonium bromide) have been assessed to be acceptable.

2.2 Method for Formulation Analysis

The method provided for the analysis of the active ingredient in Fuzzicide Solution has been assessed to be acceptable for use as an enforcement analytical method.

2.3 Methods for Residue Analysis

Spectrophotometric, colourimetric, potentiometric titration and ion chromatographic methods were provided for data generation and enforcement purposes. These methods fulfilled the requirements with regards to selectivity, accuracy and precision for use in environmental media.

3.0 Impact on Human and Animal Health

3.1 Toxicology Summary

The PMRA has conducted a detailed review of the toxicological database for ammonium bromide. The toxicology database was reduced in comparison to the current toxicology data requirements and consisted of acute toxicity studies, 4-week and 90-day dietary studies in rats, developmental and range-finding reproductive toxicity studies in rats and genotoxicity studies conducted with ammonium bromide. The 90-day dietary study included assessments of neurotoxic potential. Literature references were provided to address the toxicokinetics of ammonia and bromide. Studies conducted with sodium bromide were also submitted to supplement the ammonium bromide database, including a published article on reproductive effects and an *in vitro* chromosomal aberration assay. Although the toxicology database was reduced, further hazard characterization of ammonium bromide was not undertaken since exposure was determined to be negligible for the proposed use pattern in pulp and paper mills. For any future use expansions, the need to address several areas in the toxicology database including neurotoxicity, chronic/carcinogenicity, developmental toxicity in a second species, as well as reproductive toxicity will be reconsidered.

Ammonium bromide is of low acute toxicity by the oral and dermal routes and is considered to be moderately toxic via the inhalation route in rats. Ammonium bromide was mildly irritating to the rabbit eye, non-irritating to rabbit skin and is not considered to be a dermal sensitizer based on results from a Guinea Pig Maximization test.

Fuzzicide Solution is of low acute toxicity via the oral, dermal and inhalation routes in rats. It was non-irritating when applied to the skin of rabbits and minimally irritating to the rabbit eye. Fuzzicide Solution is not considered to be a dermal sensitizer (on the basis of the Guinea Pig Maximization test conducted with ammonium bromide technical).

According to the submitted literature, ammonium is readily absorbed following oral ingestion and is widely distributed once in systemic circulation. Ammonium is mainly metabolized in the liver, where it is primarily converted to urea and glutamine; however, conversion to glutamine can also occur in the brain and other tissues. Excretion of ammonia, which is relatively slow (60–72% excreted within 3 days of dosing), occurs primarily as urinary urea, with minimal excretion via the feces, expired air and sweat.

Bromide is rapidly and completely absorbed following oral ingestion and is distributed almost exclusively to the extracellular fluid, with some accumulation also occurring in red blood cells, cerebrospinal fluid, thyroid gland, blood vessel walls, cartilage, tendons, dentine, kidneys, urinary bladder, stomach and the eye. Elimination of bromide is slow (half-lives of approximately 12 days in humans and 3 days in rats), with excretion occurring primarily in the urine and, to a lesser extent, in the feces. Absorption, distribution and elimination of bromide appear to be linear processes, with saturation of reabsorption only occurring at extremely high

dose levels. Information in the submitted literature indicates that cross-placental transfer of bromide occurs with accumulation occurring in fetal cartilage and kidneys and that fetal elimination of bromide may be slower in comparison to elimination from the plasma and brain of maternal animals.

In subchronic toxicity studies conducted with ammonium bromide, clinical signs of toxicity (including rolling gait, hunched posture, piloerection, subdued behaviour, partially closed eyes, limpness, long claws and splayed hind limbs), decreased body weight and body weight gain and decreased organ weights were observed in both 4-week and 90-day studies. Organ weight changes were recorded in several tissues, including the epididymis, heart, prostate, salivary glands, adrenal, lung, testes, kidneys, thyroid, pituitary, liver, spleen, thymus and uterus. Gross necropsy and histopathological findings were noted in the 90-day study at the high dose (500 and 750 mg/kg bw/day in males and females, respectively); affected tissues included the lung (both sexes) as well as isolated findings in the adrenal, testes, epididymis and prostate in males and in the harderian gland in females. Blood effects (increased white blood cell parameters), alterations in clinical chemistry (decreased cholesterol and bilirubin and increased phosphate levels) and decreased urine pH were also observed in the 90-day study. A 4-week recovery period was included in the 90-day study. Following the recovery period, treatment-related effects included clinical signs of toxicity, decreased body weight and effects on haematological and clinical chemistry parameters, as well as on organ weights.

No chronic toxicity and/or carcinogenicity studies were provided for ammonium bromide.

Three genotoxicity studies were conducted with ammonium bromide, including an Ames bacterial mutation test, a mammalian gene mutation assay (conducted with mouse lymphoma cells) and an in vivo micronucleus assay. Under the conditions of the in vitro Ames and mouse lymphoma assays, there was no indication of mutagenic potential. In the in vivo mouse micronucleus assay, ammonium bromide was not observed to induce micronuclei. An in vitro chromosome aberration study conducted with sodium bromide was submitted in fulfilment of the clastogenicity data requirement. Sodium bromide was not found to induce chromosomal aberrations in human lymphocytes. However, the study was considered to be supplemental due to the test substance used and due to a lack of detail regarding the methods used in the study. No studies were provided to address the clastogenic potential of ammonia. However, information from the literature indicates that ammonia may have the potential to induce chromosomal aberrations, based on a study with workers exposed occupationally to ammonia and the results from an in vitro study conducted with chick fibroblasts.

There was evidence of increased susceptibility of the young in the rat teratology study; a second study in a non-rodent species was not provided. Maternal toxicity was evident at the highest dose tested (1000 mg/kg bw/day) and included clinical signs of toxicity and decreased body weight gain, effects that are consistent with the general toxicity observed in the subchronic studies. At this dose, one dam was also sacrificed due to severe clinical signs. Developmental toxicity was observed at all doses tested (100–1000 mg/kg bw/day). Undescended/displaced testes and skeletal variations were observed at all doses. At the high dose, decreased body weight and an increased incidence of malformations (of the kidney, spleen, uterus, ovary and thyroid) and visceral variations, as well as additional skeletal variations were noted. As fetal effects

(undescended/displaced testes and skeletal variations) were observed in the absence of signs of maternal toxicity, it suggests that young animals may be more susceptible to the effects of ammonium bromide than adult animals.

Evidence of increased susceptibility of the young was also observed in a range-finding (one-generation) reproductive toxicity study conducted with ammonium bromide; a multi-generation study was not provided. Parental toxicity, observed at the mid and high doses (3200 and 6400 ppm), included clinical signs of toxicity (similar to those observed in the other studies) and decreased body weight gain and food consumption. In offspring, increased incidence of pup mortality and decreased litter and pup weights were observed, beginning at the lowest dose tested (1600 ppm). An increased incidence of total litter loss and decreased fertility were observed (at ≥ 3200 ppm), which are indicative of reproductive toxicity. As this was a range-finding study, it was considered to be supplemental. In addition, it should be noted that this study consisted of only one generation, the pre-mating dosing period and group sizes were insufficient and microscopic examinations were not performed.

A journal article summarizing a special 3-generation reproductive toxicity study conducted with sodium bromide, in which thyroid hormones were also measured in F_0 adult animals, was submitted by the applicant. This information was considered to be supplemental to the ammonium bromide toxicity database due to the test substance used and a general lack of information regarding the details of the study methods. However, based on the available information, exposure to sodium bromide was noted to cause a reduction in fertility and offspring viability at higher dose levels (≥ 4800 ppm) and also caused decreases in thyroid hormone (thyroxine) levels at lower levels (≥ 75 ppm). The study results suggested that the effects on fertility may be mediated by males and/or females and also provided evidence that bromide crosses the placental barrier. Other effects noted in this study included decreased body weight, adrenal and uterine weights and altered white blood cell parameters in adult animals.

Potential neurotoxicity was assessed in the 90-day dietary study. Findings indicative of neurotoxicity included decreased grip strength, delayed tail flick response and increased landing foot splay. Many of the clinical signs of toxicity noted in this study were also indicative of potential neurotoxicity, including the gait and posture abnormalities, piloerection and subdued behaviour. In addition, there was a slight increase in the number of animals with histopathological nerve findings at ≥ 225 mg/kg bw/day. Some of the findings (decreased grip strength, increased landing foot splay and posture/gait abnormalities) were observed at all doses tested (100 to 750 mg/kg bw/day), indicating that neurotoxic effects occurred at the lowest dose tested. However, NOAELs and LOAELs were not established for neurotoxicity in this study, as the study was considered to be supplemental due to limitations identified with the motor activity and neuropathology data.

Breakdown products resulting from the use of ammonium bromide and determined to appear in treated paper, include chloride, bromide, ammonia and nitrate. Information was provided to address potential health concerns for these breakdown products in relation to handling treated paper. Ammonium bromide was not found to be a dermal sensitizer in the submitted sensitization study, which alleviates sensitization concerns for ammonia and bromide residues in treated paper. Chloride is used in many pulp and paper mill products, as well as in the treatment

of drinking water and swimming pool water and is not known to be associated with any dermal sensitization potential. Although no information was provided regarding the sensitization potential of nitrate, the amount of nitrate in treated paper is reportedly less than the Canadian drinking water limit for nitrate (45 mg/L; Health Canada, 2007) and is therefore not expected to be of toxicological concern with the proposed use.

A summary of the results are provided in Appendix I, Tables 1, 2 and 3.

3.2 Determination of Acceptable Daily Intake

An acceptable daily intake is not required since the proposed uses of Fuzzicide Solution do not involve direct food uses.

3.3 Determination of Acute Reference Dose

An acute reference dose is not required since the proposed uses of Fuzzicide Solution do not involve direct food uses.

3.4 Occupational and Bystander Risk Assessment

3.4.1 Toxicological Endpoints

Occupational exposure to ammonium bromide is characterized as intermittent long-term in duration and is predominately by the dermal route. Toxicological endpoints were not required because occupational exposure (handler and postapplication) was determined to be negligible.

3.4.2 Occupational Exposure and Risk

3.4.2.1 Handler Exposure and Risk

There is potential for exposure to workers mixing/loading and applying the Fuzzicide Solution. To mitigate exposure to handlers mixing, loading and applying Fuzzicide Solution, a statement limiting the use of Fuzzicide Solution to closed loading and transfer systems (i.e. dry coupling) is required to appear on the principal display panel of the Fuzzicide Solution label and the applicant is required to design their delivery system to satisfy the criteria of this definition. This requirement is expected to result in negligible exposure to occupational handlers.

3.4.2.2 Postapplication Exposure and Risk

Based on the information provided by the applicant to characterize postapplication exposure to workers exposed to treated process water in the pulp and paper mill, exposure to these workers is expected to be negligible when wearing face protection, long-sleeved shirt and long pants, chemical-resistant gloves and chemical-resistant footwear.

3.4.3 Residential Exposure and Risk

3.4.3.1 Handler Exposure and Risk

As there are no domestic class products, a residential handler assessment was not required.

3.4.3.2 Postapplication Exposure and Risk

There is potential for consumer exposure to Fuzzicide Solution and its breakdown products from contacting treated paper and paper products. Ammonia, bromide, chloride and nitrate have been identified as quantifiable in paper and paperboard treated with Fuzzicide Solution. However, there are several products currently registered for use in pulp and paper mills that are expected to have similar by-products in treated paper. Based on the low quantities of breakdown products measured in treated paper and the lack of sensitization triggers for the breakdown products identified, exposure to treated paper and paperboard products is not of concern.

3.4.4 Bystander Exposure and Risk Assessment

For bystanders, exposure is expected to be much less than that of workers and is considered negligible.

4.0 Impact on the Environment

4.1 Fate and Behaviour in the Environment

The active Fuzzicide biocide, the bromide-activated chloramine (BAC), is generated *in situ* by reacting Fuzzicide Solution, a 35% aqueous solution of ammonium bromide, with a 12.5% aqueous solution of commercially available sodium hypochlorite. BAC is, therefore, the compound that is of concern to the environment.

BAC is not persistent in the aquatic system. The half-lives of BAC were almost the same in 0.5 and 5.0 mg Cl₂/L solutions: 50.6 and 45.6 hours, respectively, at 25°C and 26.6 and 22.6 hours, respectively, at 35°C. BAC degradation products were ammonia/ammonium, nitrate, chloride, bromide, bromoform and chloroform. With the exception of ammonium, the transformation products of BAC are not expected to adsorb to sediment. Phototransformation and volatilization in water is not expected to be important routes of transformation of BAC. The presence of secondary treatment facilities minimizing effluent load from pulp and paper mills is expected to result in minimal BAC entering the environment. BAC did not adversely affect aerobic microbial activity in the treatment facilities of pulp and paper mills. Thus, these aerobic microbes will be very efficient in reducing residual BAC levels in pulp and paper mill effluents and BAC is, therefore, not expected to be found in the effluent of pulp and paper mills when Fuzzicide Solution is used at the label recommended rate.

BAC is not expected to enter the soil during its use as a slimicide in pulp and paper mills. BAC residues are, therefore, not expected to be found in the terrestrial environment.

BAC is expected to be slightly volatile due to the presence of ammonium salts, but as BAC is readily dissociable in aqueous environments and is not persistent, BAC residues are not expected in the atmosphere. Long-range transportation of BAC will not be a concern under relevant environmental conditions.

Data on the fate and behaviour of Fuzzicide Solution and BAC in the environment are summarized in Appendix I, Table 5.

4.2 Effects on Non-Target Species

To estimate risk of potential adverse effects on non-target species, a quotient method is used. The risk quotient (RQ) is calculated by dividing the exposure estimate by a value representing the most sensitive toxic endpoint. A screening-level risk assessment is initially performed using the expected environmental concentrations (EECs) for a worst-case scenario (e.g. direct overspray of a body of water) and the most sensitive toxicity endpoint. Low risk is predicted if the risk quotient is less than the trigger value of one. In these cases, no further assessment is done. For those groups of organisms for which the RQ is greater than one, a refined assessment is undertaken. A refined assessment takes into consideration more realistic exposure scenarios (e.g. drift to non-target habitats and runoff to water bodies) and may consider different toxicity endpoints.

4.2.1 Effects on Terrestrial Organisms

Fuzzicide (Ammonium Bromide) caused mortality to one bird at a concentration of 2000 mg a.i./kg when administered orally in a gelatine capsule. Clinical signs were limited to the observation of white vomit from two birds. No other clinical or sublethal effects were observed in orally treated birds. Dietary short-term exposure of birds to Fuzzicide (Ammonium Bromide) did not result in any mortality or toxicity and no treatment-related effects were observed for body weight or feed consumption in all surviving birds. Based on the use pattern, the exposure of terrestrial organisms to Fuzzicide (Ammonium Bromide) or BAC is not expected to occur. The risk assessment towards these organisms was, thus, not conducted (Appendix I, Table 6).

4.2.2 Effects on Aquatic Organisms

Risk of BAC to aquatic organisms was based upon the evaluation of toxicity data for five freshwater species (one invertebrate, two fish, one alga and one vascular plant) and three estuarine/marine species (two invertebrate and one fish) (Appendix I, Table 6).

In dose response studies, BAC caused sublethal effects at various concentrations on daphnids, mysid shrimp, all fish species and eastern oyster (NOEC values between 0.0026 mg Cl₂/L to 0.33 mg Cl₂/L). BAC was toxic to vascular plants at concentrations greater than 0.16 mg Cl₂/L. On an acute basis, BAC negatively affected biomass of the freshwater green alga at concentrations greater than 0.0075 mg Cl₂/L.

It is anticipated, however, that BAC will pose a negligible risk to aquatic organisms as the use of BAC in pulp and paper mills is not expected to result in any measurable BAC residues discharged into the aquatic environment. Label statements indicating the toxicity of this pesticide to aquatic organisms and statements to minimize exposure to the aquatic environment have been added to the product label.

5.0 Value

5.1 Effectiveness Against Pests

Data from one laboratory trial and three paper mill operational trials were submitted. Each of these studies was found to have appropriate experimental design.

Data in support of pulp and paper mill Whitewater Systems:

- The laboratory trial, a biofilm test, was conducted as a simulation of paper machine process water. Fuzzicide Solution was able to prevent the formation of slime on the stainless steel coupons at residual biocide concentrations of 2.5 and 5 ppm expressed as total chlorine. (Table 1.3.1)
- The first operational trial involved the comparison of the efficacy of Fuzzicide Solution to a HOBr-based biocidal program used within two paper machines. Fuzzicide Solution was effective in reducing planktonic bacteria within the process waters of the paper machines at residual biocide concentrations ranging between 0.5–5 ppm expressed as total chlorine.
- In a second operational trial, the time lost due to slime formation in the paper mill was recorded for a number of different biocide treatment programs over a period of nearly two years. The Fuzzicide Solution regime resulted in less slime-related downtime compared to other biocides used at the mill.

Data in support of Starch Slurries:

- The operational trial examined the use of Fuzzicide Solution in starch preservation by sampling starch from the size press circulation tanks over a period of 14 months. Fuzzicide Solution was successful in maintaining or lowering viable counts when total chlorine residuals were maintained between 1–10 ppm in the starch slurries, over the 14 month test period.

5.1.1 Acceptable Efficacy Claims

The submitted data demonstrated that Fuzzicide Solution, when used in conjunction with 12.5% sodium hypochlorite via the Fuzzicide feeder/delivery system, effectively prevented fouling caused by algae, bacteria and fungi when used at rates ranging from 0.5 to 5.0 ppm residual biocide (expressed as total chlorine) in whitewater systems and up to 10.0 ppm residual biocide (expressed as total chlorine) in starch slurries.

5.2 Sustainability

5.2.1 Survey of Alternatives

Fuzzicide Solution is an alternative slimicide for the prevention of fouling caused by bacterial, fungal and algal slimes which results in the formation of biofilms. These biofilms are formed by diverse microorganisms under a wide range of conditions. Furthermore, some biocides may be chemically incompatible with certain industrial processes or other chemicals. For this reason, it is important to have a variety of biocides available. There are numerous slimicide products currently registered in Canada for use in pulp and paper mills. These are generally broad-spectrum biocides based on a number of different active ingredients with modes of action ranging from oxidizing compounds to membrane-disrupting surfactants.

The options available for microbial slime control for use in pulp and paper mills are summarized in Table 7 of Appendix I.

5.2.2 Compatibility with Current Management Practices Including Integrated Pest Management

Fuzzicide Solution is not expected to have an impact on current microbial control practices.

5.2.3 Information on the Occurrence or Possible Occurrence of the Development of Resistance

The bromide-activated chloramine, formed during the reaction between the chlorine (sodium hypochlorite) and the ammonium bromide in the Fuzzicide Solution, is a broad-spectrum biocide that affects protein-associated processes. Long-term resistance is not expected to develop due to the mode of action and to the industry's current practice of regularly alternating slimicide products.

6.0 Toxic Substances Management Policy Considerations

The management of toxic substances is guided by the federal government's Toxic Substances Management Policy (TSMP), which puts forward a preventive and precautionary approach to deal with substances that enter the environment and could harm the environment or human health. The policy provides decision makers with direction and sets out a science-based management framework to ensure that federal programs are consistent with its objectives. One of the key management objectives is virtual elimination from the environment of toxic substances that result predominantly from human activity and that are persistent and bioaccumulative. These substances are referred to in the policy as Track-1 substances.

During the review process, Fuzzicide (Ammonium Bromide) was assessed in accordance with the PMRA Regulatory Directive [DIR99-03](#), *The Pest Management Regulatory Agency's Strategy for Implementing the Toxic Substances Management Policy*. Substances associated with the use of Fuzzicide (Ammonium Bromide) were also considered, including major transformation

products formed in the environment, microcontaminants in the technical product and formulants in the end-use product Fuzzicide Solution. The PMRA has reached the following conclusions:

- Ammonium bromide is an inorganic salt and does not meet the criteria for persistence, bioaccumulation and toxicity. Fuzzicide biocide, bromide-activated chloramine (BAC), does not meet the criteria for persistence. Its value for half-life in water (50 hours) is below the TSMP Track-1 cut-off criteria for water (≥ 182 days). BAC is an inorganic compound and is not expected to be bioaccumulative. It is readily dissociable, is highly soluble in water and of low solubility in organic solvents, therefore, its octanol–water partition coefficient ($\log K_{ow}$) will be below the TSMP Track-1 cut-off criterion of ≥ 5.0 . Fuzzicide biocide meets the criteria for toxicity. Fuzzicide biocide does not form any major transformation products that meet the TSMP Track-1 criteria. As BAC does not meet all Track-1 criteria, it is not classified as a Track-1 substance.
- Fuzzicide (Ammonium Bromide) does not contain any by-products or microcontaminants that meet the TSMP Track-1 criteria. Impurities of toxicological concern are not expected to be present in the raw materials nor are they expected to be generated during the manufacturing process.
- Fuzzicide (Ammonium Bromide) does not contain any contaminants of health or environmental concern identified in the *Canada Gazette*, Part II, Volume 139, Number 24, pages 2641–2643: *List of Pest Control Product Formulants and Contaminants of Health or Environmental Concern*.
- The end-use product Fuzzicide Solution does not contain any formulants of health or environmental concern identified in the *Canada Gazette*, Part II, Volume 139, Number 24, pages 2641–2643: *List of Pest Control Product Formulants and Contaminants of Health or Environmental Concern*.

Therefore, the use of Fuzzicide Solution is not expected to result in the entry of Track-1 substances into the environment.

7.0 Summary

7.1 Human Health and Safety

The toxicology database was reduced in comparison to current standard toxicology data requirements. Further hazard characterization of ammonium bromide was not undertaken, however, since exposure was determined to be negligible for the proposed scenario on pulp and paper. For any further use expansions, the need to address deficiencies in several areas including neurotoxicity, chronic/carcinogenicity, developmental toxicity in a second species, as well as reproductive toxicity will be reconsidered.

Mixer, loader, applicators and workers exposed to treated process water are not expected to be exposed to levels of ammonium bromide that will result in unacceptable risk when Fuzzicide Solution is used according to label directions. The label specifies the personal protective equipment required to protect workers mixing and loading Fuzzicide Solution and handling treated process water.

Exposure to individuals contacting treated paper is not expected to result in unacceptable risk when Fuzzicide Solution is used according to label directions.

7.2 Environmental Risk

Based on the use pattern for Fuzzicide Solution in pulp and paper mills, Fuzzicide biocide presents a negligible risk to aquatic organisms. Specific statements regarding its toxicity to aquatic organisms and statements to minimize exposure to the aquatic environment are provided on the product label.

7.3 Value

The submitted data indicated that Fuzzicide Solution used in conjunction with sodium hypochlorite via the Fuzzicide feeder/delivery system effectively prevented the fouling of pulp and paper mill whitewater systems and starch slurries caused by bacterial, fungal and algal contamination.

8.0 Regulatory Decision

Health Canada's PMRA, under the authority of the *Pest Control Products Act* and in accordance with the Pest Control Products Regulations, has granted conditional registration for the sale and use of technical grade active ingredient Fuzzicide (Ammonium Bromide) and the end-use product Fuzzicide Solution. An evaluation of current scientific data from the registrant, scientific reports and information from other regulatory agencies has resulted in the determination that, under the approved conditions of use, the end-use product has value and does not present an unacceptable risk to human health or the environment.

Although the risks and value have been determined to be acceptable when all risk-reduction measures are followed, as a condition of these registrations, additional scientific information is being requested from the registrant as a result of this evaluation (see below).

- **Environment**

A hydrolysis study conducted with the Fuzzicide biocide, bromide-activated chloramine, in sterile water at three different pH's (e.g. pH 4.0, pH 7.0 and pH 9.0) is required. This study is to be submitted to the PMRA by 1 September 2009.

NOTE: The PMRA will publish a consultation document at the time when there is a proposed decision on applications to convert these conditional registrations to full registrations or on applications to renew the conditional registrations, whichever occurs first.

List of Abbreviations

µg	micrograms
a.i.	active ingredient
atm	atmospheres
BAC	bromide activated chloramine
bw	body weight
CAS	chemical abstracts service
cm	centimetres
DACO	data code
DNA	deoxyribonucleic acid
EC ₁₀	effective concentration on 10% of the population
EC ₂₅	effective concentration on 25% of the population
g	gram
HOBr	hypobromous acid
IUPAC	International Union of Pure and Applied Chemistry
kg	kilogram
K_{oc}	organic-carbon partition coefficient
K_{ow}	<i>n</i> -octanol–water partition coefficient
L	litre
LC ₅₀	lethal concentration 50%
LD ₅₀	lethal dose 50%
LOAEL	lowest observed adverse effect level
LOEC	low observed effect concentration
LOQ	limit of quantitation
LR ₅₀	lethal rate 50%
mg	milligram
mL	millilitre
MAS	maximum average score
MOE	margin of exposure
m/z	mass to charge ratio
N/A	not applicable
NOAEL	no observed adverse effect level
NOEC	no observed effect concentration
NOEL	no observed effect level
N/R	not required
PMRA	Pest Management Regulatory Agency
ppm	parts per million
$t_{1/2}$	half-life
TSMP	Toxic Substances Management Policy
USEPA	United States Environmental Protection Agency

Appendix I Tables and Figures

Table 1 Acute Toxicity of Ammonium Bromide Technical and Its Associated End-use Product (Fuzzicide Solution)

Study Type	Species	Result	Comment	Reference
Acute Toxicity of Ammonium Bromide Technical				
Oral	Rat (Sprague-Dawley)	LD ₅₀ (M) = 2868 mg/kg bw LD ₅₀ (F) = 2566 mg/kg bw LD ₅₀ (M/F) = 2714 mg/kg bw	Low toxicity	665852
Dermal	Rat (Sprague-Dawley)	LD ₅₀ > 2000 mg/kg bw	Low toxicity	665853
Inhalation	Rat (Sprague-Dawley)	LC ₅₀ > 0.10 mg/L	Moderate toxicity	665854
Skin irritation	Rabbit (New Zealand White)	MAS ^a = 0	Non-irritating	665856
Eye irritation	Rabbit (New Zealand White)	MAS = 5.4	Mildly irritating	665855
Skin sensitization (Maximization)	Guinea pig	Negative	Not a dermal sensitizer	665857
Acute Toxicity of End-Use Product: Fuzzicide Solution				
Oral	Rat (Sprague-Dawley)	LD ₅₀ > 5000 mg/kg bw	Low toxicity	665948
Dermal	Rat (Sprague-Dawley)	LD ₅₀ > 5000 mg/kg bw	Low toxicity	665949
Inhalation	Rat (Sprague-Dawley)	LC ₅₀ > 4.21 mg/L	Low toxicity	665950
Skin irritation	Rabbit (New Zealand White)	MAS = 0	Non-irritating	665952
Eye irritation	Rabbit	MAS = 2	Minimally irritating	665951
Skin sensitization (not provided)	N/A	Negative (based on study conducted with ammonium bromide technical)	Not a dermal sensitizer	665857

^a MAS = maximum average score for 24, 28 and 72 hours

Table 2 Toxicity Profile of Ammonium Bromide Technical

Study Type	Species	Results ^a (mg/kg/day)	Reference
28-day dietary	Rat (Sprague-Dawley)	A NOAEL and LOAEL were not established since the study is considered to be supplemental. Decreased absolute testes weights were noted at 100 mg/kg bw/day. Effects noted at the next highest dose (500 mg/kg bw/day) included clinical signs of toxicity, decreased body weight and body weight gain and decreased absolute epididymis, heart, kidneys, testes, lung and liver weights.	665858
90-day dietary Complete functional operational battery, motor activity and neurohistopathology assessments also performed	Rat (Sprague-Dawley)	NOAEL: not established LOAEL: 100 mg/kg bw/day; clinical signs of toxicity (long claws), decreased cholesterol and increased phosphate levels (F), decreased absolute brain, thyroid, kidney, liver, testes and epididymis weights (M) and increased haemoglobin levels (M). A NOAEL and LOAEL for neurotoxicity were not established since the neurotoxicity component of the study was considered to be supplemental. Effects indicative of neurotoxicity were observed at 100 mg/kg bw/day (the lowest dose tested), including decreased hindlimb grip strength (M/F) and increased landing foot splay, posture/gait abnormalities and limpness (M).	665859 930894 930896
One-generation reproduction	Rat (Sprague-Dawley)	NOAELs and LOAELs were not established since the study is considered to be supplemental. Parental: No effects were noted at 151/176 mg/kg bw/day (M/F). Effects noted at the next highest dose (277/347 mg/kg bw/day [M/F]) included clinical signs of toxicity (F) and decreased body weight gain and food consumption (M). Offspring: At 151/176 mg/kg bw/day (M/F; the lowest dose tested), one pup was sacrificed in extremis (signs of toxicity included cold to touch, subdued behaviour and abnormal breathing). Reproductive: No effects were noted at 151/176 mg/kg bw/day (M/F). At the next highest dose (277/347 mg/kg bw/day [M/F]), decreased pup viability was observed (one litter with all pups born dead).	1093412
Developmental toxicity	Rat (Sprague-Dawley)	Maternal NOAEL: 300 mg/kg bw/day Maternal LOAEL: 1000; clinical signs of toxicity, decreased body weight gain and one dam sacrificed due to severe clinical signs. Developmental NOAEL: not established Developmental LOAEL: 100; increased incidence of undescended/displaced testes and skeletal variations.	665862

Study Type	Species	Results ^a (mg/kg/day)	Reference
Reverse gene mutation assay	<i>Salmonella typhimurium</i> / <i>E.coli</i>	Negative	665849
In vitro mammalian gene mutation assay	Mouse Lymphoma L5178Y cells	Negative	665850
In vivo mammalian cytogenetics	Mouse micro nucleus assay	Negative	665851

^a Effects observed in males as well as females unless otherwise reported

Table 3 Toxicity Studies Conducted with Sodium Bromide

Study Type	Species	Results ^a (mg/kg/day)	Reference
Special Reproduction Investigations (3-Generations; 2 litters/generation)	Rat (strain not specified)	<p>NOAELs and LOAELs were not established since the study is considered to be supplemental.</p> <p>Parental: Effects were noted for males at 75 ppm (3.7 mg/kg bw/day), including decreased thyroid hormone (thyroxine) levels and decreased body weight (F₂).</p> <p>For females, no effects were noted at 300 ppm (15 mg/kg bw/day). Effects noted at the next highest dose (1200 ppm; 60 mg/kg bw/day) included decreased body weight (F₂) and decreased adrenal (F₀) and uterine weights (F₁).</p> <p>Offspring: No effects were noted at 1200 ppm (15 mg/kg bw/day). Decreased offspring viability was noted at the next highest dose (4800 ppm; 240 mg/kg bw/day).</p> <p>Reproductive: No effects were noted at 1200 ppm (15 mg/kg bw/day). Decreased fertility was noted at the next highest dose (4800 ppm; 240 mg/kg bw/day).</p>	665861
In vitro chromosome aberrations	Human lymphocyte cells	<p>Negative</p> <p>Supplemental: Lack of detail regarding study methods.</p>	1093414

Study Type	Species	Results ^a (mg/kg/day)	Reference
Metabolism: Various literature references		<p>Absorption Bromide is rapidly and completely absorbed following oral ingestion.</p> <p>Distribution Bromide is distributed almost exclusively to the extracellular fluid, with some accumulation also occurring in red blood cells, cerebrospinal fluid, thyroid gland, blood vessel walls, cartilage, tendons, dentine, kidneys, urinary bladder, stomach and the eye.</p> <p>Excretion Elimination of bromide is slow (half-lives of approximately 12 days in humans and 3 days in rats); excretion primarily in the urine and to a lesser extent in the feces.</p> <p>Absorption, distribution and elimination of bromide appear to be linear processes, with saturation of reabsorption only occurring at extremely high dose levels. Information in the literature indicates that cross-placental transfer of bromide occurs, with accumulation occurring in fetal cartilage and kidneys and that fetal elimination of bromide may be slower in comparison to elimination from the plasma and brain of maternal animals.</p>	665863 665864 934180 1424675

^a Effects observed in males as well as females unless otherwise reported

Table 4 Toxicity Studies Conducted with Ammonia

Study Type	Species	Results ^a (mg/kg/day)	Reference
In vitro chromosome aberrations (literature information)		<p>Positive: Information from the literature indicates that ammonia may have the potential to induce chromosomal aberrations, based on a study with workers exposed occupationally to ammonia and the results from an in vitro study conducted with chick fibroblasts.</p>	1093415
Metabolism: Various literature references		<p>Absorption Ammonium is readily absorbed following oral ingestion.</p> <p>Distribution Ammonium is widely distributed once it reaches circulation.</p> <p>Excretion Excretion is relatively slow (60-72% excreted within 3 days of dosing) and occurs primarily as urinary urea, with minimal excretion via the feces, expired air and sweat.</p> <p>Metabolism Ammonium is mainly metabolized in the liver, where it is primarily converted to urea and glutamine. Conversion to glutamine can also occur in brain and other tissues.</p>	1093415

^a Effects observed in males as well as females unless otherwise reported

Table 5 Fate and Behaviour in the Environment

Property	Test substance	Value	Comments	Reference (PMRA #)
Soil				
Hydrolysis	BAC	NA	Study required	
Phototransformation on soil	BAC	No data required.	Low potential for phototransformation under environmentally relevant conditions	
Phototransformation in air	BAC	No data required.	Low volatilization potential under environmentally relevant conditions	
Biotransformation in aerobic soil	BAC	No data required.	Exposure to soil is not expected.	
Biotransformation in anaerobic soil	BAC	No data required.	Exposure to soil is not expected.	
Adsorption/desorption in soil	BAC	Waiver accepted.	Exposure to soil is not expected.	930988
Soil leaching	BAC	Data not required.	Exposure to soil is not expected.	
Volatilization	BAC	No data required.	Volatilization is not expected to be a concern.	
Field dissipation	BAC	Data not required.	Exposure to soil is not expected.	
Field leaching	BAC	Data not required.	Exposure to soil is not expected.	
Aquatic systems				
Hydrolysis	BAC	N/A	Study required.	
Phototransformation in water	BAC	Waiver accepted.	Low potential for phototransformation under environmentally relevant conditions	665879

Property	Test substance	Value	Comments	Reference (PMRA #)
Biotransformation in aerobic water systems	BAC	Half-life at 5.0 mg Cl ₂ : 25°C: 50.6 hours 35°C: 26.6 hours Half-life at 0.5 mg Cl ₂ : 25°C: 45.6 hours 35°C: 22.6 hours		665867
Biotransformation in anaerobic water systems	BAC		Not expected to be an issue.	
Adsorption/desorption in sediment	BAC	Waiver accepted.	Not expected to be an issue	930988
Field dissipation: Pulp and paper mill	BAC	Not detected at outlet	BAC was not detected in the effluent that was discharged into the environment.	1093417

Table 6 Effects on Terrestrial and Aquatic Organisms

Organism	Species	Study Type	Test substance	Endpoint value	Reference (PMRA #)
Terrestrial organisms					
Bird	Mallard duck	Acute single oral dose	Fuzzicide (ammonium bromide)	NOEL: 1600 mg a.i./kg bw LD ₅₀ : > 2000 mg a.i./kg bw	665869
		Dietary 5-day exposure	Fuzzicide (ammonium bromide)	NOEC: 5000 mg a.i./kg diet LC ₅₀ : > 5000 mg a.i./kg diet	665878
		Reproduction	Fuzzicide (ammonium bromide)	Not required	
	Bobwhite quail	Acute	Fuzzicide (ammonium bromide)	Waiver accepted	931039
Vascular plant		Seedling emergence	Fuzzicide (ammonium bromide)	Not required	
		Vegetative vigour	Fuzzicide (ammonium bromide)	Not required	

Organism	Species	Study Type	Test substance	Endpoint value	Reference (PMRA #)
Freshwater species					
Invertebrates	<i>Daphnia magna</i>	Acute	BAC	48-h NOEC: 17 µg Cl ₂ /L (based on sublethal effects) 48-h EC ₅₀ : 23.3 µg Cl ₂ /L	665870
		Chronic	BAC	Waiver accepted	931006
Fish	Rainbow trout	Acute	BAC	96-h NOEC: 14 µg Cl ₂ /L (based on sublethal effects) 96-h LC ₅₀ : 57.33 µg Cl ₂ /L	665873
		Chronic	BAC	Not required	
	Bluegill sunfish	Acute	BAC	96-h NOEC: 0.072 mg Cl ₂ /L 96-h LC ₅₀ : 0.33 mg Cl ₂ /L	665875
		Chronic	BAC	Not required	
Algae	Green alga	Acute	BAC	72-hr EC ₁₀ : 0.0075mg Cl ₂ /L (based on biomass inhibition) 72-hr EC ₅₀ : 0.017 mg Cl ₂ /L	665879
Plant	<i>Lemna gibba</i>	Dissolved	BAC	7-day NOEC: 0.16 mg Cl ₂ /L 7-day LC ₅₀ : 0.61mg Cl ₂ /L	665880
Marine species					
Invertebrates	Mysid shrimp	Acute	BAC	96-h NOEC: 17 µg Cl ₂ /L 96-h LC ₅₀ : 35.4 µg Cl ₂ /L	665871
		Chronic	BAC	Not required	
	Mollusk	Acute	BAC	96-h NOEC: 2.6 µg Cl ₂ /L 96-h EC ₅₀ : 18 µg Cl ₂ /L (based on reduction in shell deposition)	665872
		Chronic	BAC	Not required	

Organism	Species	Study Type	Test substance	Endpoint value	Reference (PMRA #)
Fish	Sheepshead minnow			96-h NOEC: 0.24 mg Cl ₂ /L 96-hour LC ₅₀ : 0.36 mg Cl ₂ /L	665877
	Salmonid	Acute	BAC	Waiver accepted.	931033
		Salinity challenge	BAC	Waiver accepted.	931033

Table 7 Alternative Slimicides for Pulp and Paper Mill Use

Active	Example of End-Use Product	Claims	Mode of Action
1,2-DIBROMO-2,4-DICYANOBTANE	Tektamer 2200	bacteria; fungi; yeasts	cellular oxidation
1-BROMO-3-CHLORO-5,5-DIMETHYLHYDANTOIN 1,3-DICHLORO-5,5-DIMETHYLHYDANTOIN 1,3-DICHLORO-5-ETHYL-5 METHYLHYDANTOIN	B.I.O. Blast 650	microbial slimes	cellular oxidation
1-ALKYL (C8-C18)-1,3-PROPANEDIAMINE ACETATE	Rasio 936	bacterial & fungal slimes	unknown
1-BROMO-3-CHLORO-5,5-DIMETHYLHYDANTOIN	Aquate	slime-forming bacteria; fungi; algae	cellular oxidation
2,2-DIBROMO-3-NITRILOPROPIONAMIDE	Fennosan 150-C	bacteria; fungi; yeast	cellular oxidation
2-METHYL-4-ISOTHIAZOLIN-3-ONE 5-CHLORO-2-METHYL-4-ISOTHIAZOLIN-3-ONE	Irgacide PT 286X	slime-forming bacteria; fungi	inhibition of membrane-bound enzymes
BRONOPOL	Rasio 937	slimicide	cellular oxidation
DAZOMET	Amerstat 223	slime-forming bacteria; fungi	unknown
DECYL ISONONYL DIMETHYL AMMONIUM CHLORIDE	Bardac CW-50	bacteria; fungi; algae	membrane disruption
GLUTARALDEHYDE N-ALKYL (40% C12, 50% C14, 10% C16) DIMETHYL BENZYL AMMONIUM CHLORIDE	Nalcon 7637	slime-forming bacteria; sulfate-reducing bacteria; fungi; yeast	protein cross-linking; membrane disruption

Active	Example of End-Use Product	Claims	Mode of Action
GLUTARALDEHYDE	Prior 285	slime-forming bacteria; sulfate-reducing bacteria; fungi; yeast	protein cross-linking
METHYLENE BIS(THIOCYANATE)	Process B-2008	slime-forming and spoilage bacteria	protein alteration
NABAM; SODIUM DIMETHYLDITHIOCARBAMATE	X-Cell 419	papermill slimes	unknown
N-ALKYL (40% C12, 50% C14, 10% C16) DIMETHYL BENZYL AMMONIUM CHLORIDE	Process B-1001	slime-forming bacteria	membrane disruption
SODIUM BROMIDE (+ HYDROCHLORIC ACID)	Basabrom 40	slime-forming bacteria; fungi; algae	cellular oxidation

Table 8 Unsupported Proposed Use (label) Claims

Applicant-proposed Label Claims	Accepted Label Claims	Unsupported Label Claims and Comment
<p><u>RECIRCULATING COOLING SYSTEMS</u> Used effectively at recommended dosage to achieve measured concentration of 0.3–5.0 ppm residual biocide expressed as total chlorine, or as needed to maintain control of algal, bacterial, and fungal slimes in industrial cooling towers, heat exchange water towers, industrial water scrubbing systems, brewery and canning pasteurizers and industrial air washing systems equipped with mist eliminator, influent systems such as flow through filters and lagoons, etc.</p> <p><u>Dosage Rates</u> <u>Initial dose:</u> When noticeably fouled, add sufficient biocide produced by the feeder to achieve a measured concentration of 0.3–5.0 ppm residual biocide, expressed as total chlorine. The recommended dosage is typically achieved by mixing 2.03 litres of Sodium Hypochlorite (12.5%) with 1.0 kg (0.83 litres) of FUZZICIDE SOLUTION in the feeder.</p> <p><u>Subsequent Dose:</u> Once microbial control is evident, add sufficient biocide produced by the feeder to maintain the measured residual biocide concentration at 0.3–5.0 ppm in process waters, expressed as total chlorine. Continue as in initial dose.</p>	<p>PULP AND PAPER MILLS: Used for the prevention of algal, bacterial and fungal slimes, in pulp and paper mill whitewater systems and starch slurries. Badly fouled process systems must be cleaned before initial treatment. Total chlorine residuals can be monitored using a DPD standard chlorine test kit.</p> <p><u>Whitewater Systems:</u> Add sufficient biocide produced by the feeder to achieve and maintain a measured concentration of 0.5–5.0 ppm residual biocide, expressed as total chlorine.</p> <p><u>Starch Slurries:</u> Add sufficient biocide produced by the feeder to achieve and maintain a measured residual biocide concentration of up to 10.0 ppm in process waters, expressed as total chlorine.</p>	<p>RECIRCULATING COOLING SYSTEMS: Used effectively at recommended dosage to achieve measured concentration of 0.3–5.0 ppm residual biocide expressed as total chlorine, or as needed to maintain control of algal, bacterial and fungal slimes in industrial cooling towers, heat exchange water towers, industrial water scrubbing systems, brewery and canning pasteurizers and industrial air washing systems equipped with mist eliminator, influent systems such as flow through filters and lagoons, etc.</p> <p><u>Dosage Rates</u> <u>Initial dose:</u> When noticeably fouled, add sufficient biocide produced by the feeder to achieve a measured concentration of 0.3–5.0 ppm residual biocide, expressed as total chlorine. The recommended dosage is typically achieved by mixing 2.03 litres of Sodium Hypochlorite (12.5%) with 1.0 kg (0.83 litres) of FUZZICIDE SOLUTION in the feeder.</p> <p><u>Subsequent Dose:</u> Once microbial control is evident, add sufficient biocide produced by the feeder to maintain the measured residual biocide concentration at 0.3–5.0 ppm in process waters, expressed as total chlorine. Continue as in initial dose.</p>

Applicant-proposed Label Claims	Accepted Label Claims	Unsupported Label Claims and Comment
<p><u>PULP AND PAPER MILLS</u> Used for the control of algal, bacterial and fungal slimes, in pulp and paper mill fresh water influent systems, cooling water systems, wastewater treatment systems, pulp, paper and paper board mills systems, non potable water systems, starch slurries and other process water. Apply biocide as directed.</p> <p><u>Dosage Rates</u> <u>Initial dose:</u> When noticeably fouled, add sufficient biocide produced by the feeder to achieve a measured concentration of 0.3–10.0 ppm residual biocide, expressed as total chlorine. The recommended dosage is typically achieved by mixing 2.03 litres of Sodium Hypochlorite (12.5%) with 1.0 kg (0.83 litre) of FUZZICIDE SOLUTION in the feeder.</p> <p><u>Subsequent Dose:</u> Once microbial control is evident, add sufficient biocide produced by the feeder to maintain the measured residual biocide concentration at 0.3–10.0 ppm in process waters, expressed as total chlorine.</p>		

List of References

A. LIST OF STUDIES/INFORMATION SUBMITTED BY REGISTRANT

1.0 Chemistry Assessment

PMRA Document Number	Reference
1093422	2005, Bromide Activated Chloramine Product Identification, DACO: 2.16
1093424	2005, Response to Deficiency Notes regarding DACO 2.13.1-2.13.3, DACO: 2.13.1
1093425	2005, Expert Statement regarding choice of method of analyses for determination of bromide and chloride, SPL Project Number 466/246, DACO: 2.13.3
1093426	1992, CRC Handbook Excerpts, DACO: 2.14.7
1113014	2004, Fuzzicide Solution - Submission 2003-3505 Answers to PMRA's questions of April 29, 2004: [characterization of onsite biocide], DACO: 2.16
1127283	2005, Deficiency Response – Submission 2003-3503 October 31, 2005, DACO: 2.13,2.14.13,2.14.7,2.14.8,4.5.1,4.5.3,4.5.6,4.5.9,8.2.2,8.2.2.2,8.2.2.3,8.2.2.4,8.2.2.5,8.2.4.1,8.2.4.2,9.1,9.5.2.4.1,9.6.2.2,9.6.2.4,9.6.2.5,9.9
1191560	2006, response to Clarifax, DACO: 2.14.3
1261940	Chemistry Requirements Bromine Compounds Limited, DACO: 2.1,2.2,2.3,2.4,2.5,2.6,2.8,2.9
1261941	Manufacturing summary, Description of starting materials, Description of production process. Flow diagram of production process of ammonium bromide. Discussion of Formation of Impurities., DACO: 2.11.1,2.11.2,2.11.3,2.11.4
1261942	Establishing certified limits, DACO: 2.12.1
1261943	Methodology/Validation, Confirmation of identity, Analytical Profile of Batches, DACO: 2.13.1,2.13.2,2.13.3
1261944	2003, Fuzzicide (Ammonium Bromide): Analytical Profile of Batches, 466/246, DACO: 2.13.3
1261945	1998, Physical & Chemical Characteristics Of Ammonium Bromide: Selected Studies to Fulfil Guideline Series 63 in Accordance with 40 CFR Part 158.190, 15406, DACO: 2.14.13,2.14.4,2.14.6,2.14.7,2.14.9,2.16
1261947	1999, Physical & Chemical Characteristics of Ammonium Bromide: Storage Stability & Corrosion Characteristics, 15838;377325, DACO: 2.14.1,2.14.14,2.14.2,2.16

- 1261961 Chemical and Physical Properties, DACO:
2.14.1,2.14.13,2.14.14,2.14.2,2.14.3,2.14.4,2.14.6,2.14.7,2.14.8,2.14.9,2.16
- 665947 2003, Storage Stability & Corrosion Characteristics (Continuing Study), Project R&D 8650-35/1, MRID: 45878301, DACO: 3.5.10,3.5.14
- 665959 2003, Certificate of Analysis, Batch 010704, 466/247, DACO: 3.4
- 665960 2003, Fuzzicide Solution, Assessment of Hazardous Physico-Chemical Properties, 466/249, DACO: 3.5
- 665961 2003, Fuzzicide Solution - Determination of Viscosity & Surface Tension, 466/248, MRID: 45787302, DACO: 3.5.9
- 665962 2003, Storage Stability & Corrosion Characteristics (Accelerated Study), Project R&D 8650-35/1, MRID: 45787302, DACO: 3.5.14
- 901124 CHEMISTRY REQUIREMENTS, DACO: 3.0
- 1093460 2005, Response to Deficiency Notes regarding DACO 3.4.1 of Fuzzicide Solution (EP), DACO: 3.4.1
- 1093461 2004, Fuzzicide Solution (Ammonium Bromide 35% Solution) Storage Stability and Corrosion Characteristics, DSBG Project No:R&D 8650-35/1, DACO: 3.5.10,3.5.14
- 1093416 2001, Health Canada and Environment Canada, Canadian Environmental Protection Act, 1999: Priority Substances List Assessment Report - Inorganic Chloramines, DACO: 8.2.2
- 1093417 2005, Analysis of bromide-activated chloramine following use of Spectrum RX3898 (Fuzzicide Solution) in the process, effluent and receiving waters of a paper mill under actual use conditions, 8650-SW2004, DACO: 8.2.2.3
- 665867 2000, Fuzzicide (Ammonium Bromide) - Determination of the Abiotic Degradation by Hydrolysis in Natural Waters, 11192.6129, MRID: 45205203, DACO: 8.2.3.2

2.0 Impact on Human and Animal Health

Toxicology Assessment

PMRA Document Number	Reference
665948	2002, Fuzzicide Solution (Ammonium Bromide 35% solution): Acute Oral Toxicity in the Rat - Up and Down Procedure, Project no. 466/225, MRID: 45811201, DACO: 4.6.1

-
- 665949 2002, Fuzzicide Solution (Ammonium Bromide 35% solution): Acute Dermal Toxicity (Limit Test) in the Rat, Project no. 466/220, MRID: 45811202, DACO: 4.6.2
- 665950 2002, Fuzzicide Solution (Ammonium Bromide 35% solution): Acute Inhalation Toxicity (Nose Only) Study in the Rat, Project no. 466/219, MRID: 45799301, DACO: 4.6.3
- 665951 2002, Fuzzicide Solution (Ammonium Bromide 35% solution): Acute Eye Irritation in the Rabbit, Project no. 466/222, MRID: 45811203, DACO: 4.6.4
- 665952 2002, Fuzzicide Solution (Ammonium Bromide 35% solution): Acute Dermal Irritation in the Rabbit, Project no. 466/221, MRID: 45811204, DACO: 4.6.5
- 1093462 2004, Toxicological Profile for Ammonia, DACO: 4.7.7
- 1093463 2004, Facts on the Bromide Ion, DACO: 4.7.7
- 1093464 2004, PMRA list of Formulants., REG2004-01, DACO: 4.7.7
- 1093465 2004, Food and Drugs Act and Regulations. Part 1, Table XI., DACO: 4.7.7
- 1093466 1995, Toxicity Summary for Nitrates, DACO: 4.7.7
- 1093514 2003, 2003 Amendments Food and Drugs Act and Food and Drug Regulations (Excerpts), Catalogue No. 2003 Amendments: H41-1/2003-1E, DACO: 4.7.7
- 665849 1998, Ammonium bromide: Testing for mutagenic activity with Salmonella typhimurium TA1535, TA1537, TA 98 and TA 100 and Escherichia coli WP2uvrA, in accordance with 40 CFR Part 798.5265, 15372, MRID: 447213-09, DACO: 4.5.4
- 665850 1998, Mouse lymphoma mutation assay in accordance with 40 CFR Part 798.5300, 15518, MRID: 447213-11, DACO: 4.5.5
- 665851 1998, Ammonium bromide: Micronucleus testing in bone marrow of CD-1 mice in accordance with 40 CFR part 798.5395, 15528, MRID: 447213-10, DACO: 4.5.7
- 665852 1986, Ammonium Bromide: Acute Oral Toxicity in the Rat, 86/DSB008/452, MRID: 447213-03, DACO: 4.2.1
- 665853 1998, Ammonium bromide: Acute dermal toxicity (LD50) test in rats, 15450, MRID: 447213-04, DACO: 4.2.2
- 665854 1998, Ammonium bromide: Acute inhalation toxicity study in rats (Limit test), 15367, MRID: 447213-05, DACO: 4.2.3
- 665855 1986, Ammonium Bromide: Acute Eye Irritation/Corrosion test in the Rabbit, 86/DSB010/447, MRID: 447213-06, DACO: 4.2.4
- 665856 1986, Ammonium Bromide: Acute Dermal Irritation/Corrosion test in the Rabbit, 86/DSB009/43, MRID: 47213-07, DACO: 4.2.5
-

-
- 665857 1998, Ammonium bromide: Magnusson-Kligman maximisation test in guinea pigs, 15447, MRID: 447213-08, DACO: 4.2.6
- 665858 1999, Ammonium Bromide 4 Week Dose Range-Finding Study in Rats with Administration by the Diet, 17083, MRID: 45139301, DACO: 4.3.1
- 665859 2000, Ammonium Bromide 13 Week Toxicity Study in Rats with Administration by the Diet with Neurotoxicity Screening Battery, 18612, MRID: 45210801, DACO: 4.3.1
- 665860 2000, Human Health Risk Assessment of Ammonium Bromide (NH₄Br), 8650-RA, DACO: 4.5.1
- 665861 van Leeuwen, F. et al., 1983, Toxicity of sodium bromide in rats: Effects on endocrine system and reproduction, Fd Chem. Toxic. 21 (4): 383-389, DACO: 4.5.1
- 665862 1999, Ammonium bromide: Developmental Toxicity Study in Rats, 17175, MRID: 45139302, DACO: 4.5.2
- 665863 van Leeuwen, R. and Sangster, B., 1987, The Toxicology of bromide ion, CRC Critical Reviews in Toxicology. 18 (3): 189-213, DACO: 4.5.9
- 665864 Rauws, A., 1983, Pharmacokinetics of bromide ion: An overview, I1983, Fd Chem. Toxic. 21 (4): 379-382, DACO: 4.5.9
- 930894 2000, Ammonium Bromide 13 Week Toxicity Study in Rats with Administration by the Diet with Neurotoxicity Screening Battery, 18612, MRID: 45210801, DACO: 4.3.1
- 930896 2000, Ammonium Bromide 13 Week Toxicity Study in Rats with Administration by the Diet with Neurotoxicity Screening Battery, 18612, MRID: 45210801, DACO: 4.3.1
- 930910 2002, COMBINED CHRONIC/ONCOGENICITY (RODENT): REQUEST FOR WAIVER, DACO: 4.4.4
- 930914 2002, MULTIGENERATION-REPRODUCTION (RODENT): REQUEST FOR WAIVER, DACO: 4.5.1
- 930918 2002, TERATOGENICITY (NON-RODENT); REQUEST FOR WAIVER, DACO: 4.5.3
- 934180 2002, METABOLISM/TOXICOKINETICS: REQUEST FOR WAIVER., DACO: 4.5.9
- 1093412 2001, Ammonium Bromide Dose Range Finding Reproduction Study in Rats, 17372, DACO: 4.5.1
- 1093413 2005, Evaluation of the Potential Health Risks for Fuzzicide Solution (35% Ammonium Bromide) when used in Cooling Water Systems and Pulp and Paper Mills, DACO: 4.5.3
-

- 1093414 1988, Sodium Bromide Technical Grade Metaphase Chromosome Analysis of Hume Lymphocytes Cultured In Vitro, DSB 5/88447, DACO: 4.5.6
- 1093415 Gerberding, J., 2004, US EPA, Toxicological Profile for Ammonia, Federal Register. April 17, 1987, DACO: 4.5.9
- 1421675 Vaiseman, N., Koren, G., Pencharz, P., Pharmacokinetics of Oral and Intravenous Bromide in Normal Volunteers, Clinical Toxicology, 24(5), 403-413 (1986), DACO: 4.5.9

Occupational Risk Assessment

PMRA Document Number	Reference
----------------------	-----------

- | | |
|---------|---|
| 1421938 | May 1, 2007; Worker Exposure in Paper Mills |
|---------|---|

3.0 Impact on the Environment

PMRA Document Number	Reference
----------------------	-----------

- | | |
|--------|---|
| 665867 | 2000, Fuzzicide (Ammonium Bromide) - Determination of the Abiotic Degradation by Hydrolysis in Natural Waters, 11192.6129, MRID: 45205203, DACO: 8.2.3.2 |
| 665868 | 2000, Fuzzicide (Ammonium Bromide) - Activated Sludge Respiration Inhibition, 11192.6128, MRID: 45205204, DACO: 8.2.3.2 |
| 665869 | 1998, Acute oral toxicity study in the mallard duck, 15568, MRID: 447213-01, DACO: 9.6.2.2 |
| 665870 | 1998, Fuzzicide (Ammonium Bromide) Acute toxicity to Daphnids (<i>Daphnia magna</i>) under flow-through conditions, Report no. 98-2-7258, MRID: 44721314, DACO: 9.3.2 |
| 665871 | 1998, Fuzzicide (Ammonium Bromide) Acute toxicity to Mysids (<i>Mysidopsis bahia</i>) under flow-through conditions, 98-3-7271, MRID: 447213-15, DACO: 9.4.2 |
| 665872 | 1998, Fuzzicide (Ammonium Bromide) Acute toxicity to Eastern oyster (<i>Crassostrea virginica</i>) under flow-through conditions, 98-3-7277, MRID: 447213-17, DACO: 9.4.4 |
| 665873 | 1998, Fuzzicide (Ammonium Bromide) Acute toxicity to Rainbow trout (<i>Oncorhynchus mykiss</i>) under flow-through conditions, 98-3-7274, MRID: 447213-13, DACO: 9.5.2.1 |

- 665875 1998, Fuzzicide (Ammonium Bromide) Acute toxicity to to Bluegill sunfish (*Lepomis macrochirus*) under flow-through conditions, 98-3-7266, MRID: 447213-12, DACO: 9.5.2.2
- 665877 1998, Fuzzicide (Ammonium Bromide) Acute toxicity to to Sheepshead minnow (*Cyprinodon variegatus*) under flow-through conditions, 98-3-7272, MRID: 447213-16, DACO: 9.5.2.3
- 665878 1998, Acute dietary toxicity in the mallard duck, 15574, MRID: 447213-02, DACO: 9.6.2.5
- 665879 2000, Fuzzicide (Ammonium Bromide) - Toxicity to the Freshwater Green Alga, *Pseudokirchneriella subcapitata*, 11192.6132, MRID: 45205201, DACO: 9.8.2
- 665880 2000, Fuzzicide (Ammonium Bromide) - Toxicity to Duckweed, *Lemna gibba*, 11192.6134, MRID: 45205202, DACO: 9.8.5
- 930974 SUMMARY OF PHYSICOCHEMICAL PROPERTIES, DACO: 8.2.1
- 930988 2002, ADSORPTION/DESORPTION: REQUEST FOR WAIVER, DACO: 8.2.4.2
- 931006 2002, DAPHNIA SP. CHRONIC (LIFE-CYCLE): REQUEST FOR WAIVER, DACO: 9.3.3
- 931033 2003, MARINE/ESTUARINE FISH: REQUEST FOR WAIVER, DACO: 9.5.2.4
- 931039 2002, ORAL (LD50) BOBWHITE QUAIL; DIETARY BOBWHITE QUAIL: REQUEST FOR WAIVER, DACO: 9.6.2.1,9.6.2.4
- 1093417 2005, Analysis of bromide-activated chloramine following use of Spectrum RX3898 (Fuzzicide Solution) in the process, effluent and receiving waters of a paper mill under actual use conditions, 8650-SW2004, DACO: 8.2.2.3

4.0 Value

PMRA Document Number	Reference
644162	Comprehensive Data Summaries; Economical and Environmental Benefits; Fuzzicide Solution, DACO: 10.1,12.7
665955	2001, Fuzzicide (Ammonium Bromide) Determination of the Efficacy of Microbicides Used in Cooling Water Systems, Springborn Laboratories, Inc., Study no. 11192.6130, DACO: 10.2.3.2
665956	2000, Fuzzicide (Ammonium Bromide) Results of a Field Trial, Plainwell Paper Mill, Plainwell, Michigan, A.Y. Laboratories, Study no. 8650-AY2000/1, DACO: 10.2.3.4

-
- 901244 VALUE - SUMMARIES; APPLICATION FOR REGISTRATION OF FUZZICIDE (AMMONIUM BROMIDE) USE SITE CATEGORY (USC#17): INDUSTRIAL PROCESS FLUIDS DATA ON THE EP, DACO: 10.1
- 901416 VALUE - MODE OF ACTION; APPLICATION FOR REGISTRATION OF FUUICID (AMMONIUM BROMIDE) USE SITE CATEGORY (USC#17): INDUSTRIAL PROCESS FLUIDS DATA ON THE EP, DACO: 10.2.1
- 901437 VALUE - DESCRIPTION OF PEST PROBLEM; APPLICATION FOR REGISTRATION OF FUUICID (AMMONIUM BROMIDE) USE SITE CATEGORY (USC#17): INDUSTRIAL PROCESS FLUIDS DATA ON THE EP, DACO: 10.2.2
- 901442 VALUE - EFFICACY TRIALS - SUMMARIES; APPLICATION FOR REGISTRATION OF FUUICID (AMMONIUM BROMIDE) USE SITE CATEGORY (USC#17): INDUSTRIAL PROCESS FLUIDS DATA ON THE EP, DACO: 10.2.3.1
- 901447 VALUE - ADVERSE EFFECTS ON USE SITE; APPLICATION FOR REGISTRATION OF FUZZICIDE (AMMONIUM BROMIDE) USE SITE CATEGORY (USC#17): INDUSTRIAL PROCESS FLUIDS DATA ON THE EP, DACO: 10.3
- 901453 VALUE - SUSTAINABILITY; APPLICATION FOR REGISTRATION OF FUUICID (AMMONIUM BROMIDE) USE SITE CATEGORY (USC#17): INDUSTRIAL PROCESS FLUIDS DATA ON THE EP, DACO: 10.5
- 1093445 2001, Fuzzicide Solution: Justification for the Proposed Label Feed Rate, AYLab, DACO: 10.2.3
- 1093452 2005, Fuzzicide (Ammonium Bromide) Results of a Field Trial Plainwell Paper Mill, Plainwell Michigan Second Phase January 5-14, 2000, 8650-AY2000/1, DACO: 10.2.3.4
- 1093453 2005, Use of Fuzzicide Solution as a Starch Preservative., DACO: 10.2.3.4
- 1093454 2005, Efficacy of Fuzzicide Biocide Against Established Biofilm in a Paper Mill. report Describing follow up of a paper mill during MAy 2001., DACO: 10.2.3.4
- 1093455 2001, EMC TEST CERTIFICATE, K40060.00, DACO: 10.6
- 1093459 2005, Response to Deficiency Notes regarding Fuzzicide Solution (EP), DACO: 10.1,2.16,3.1,4.1,5.1
- 1121078 Use of Fuzzicide Solution as a Starch Preservative; Efficacy of Biocides in Enzymatic Starch, DACO: 10.2.3.4
- 1093444 2001, Priority Substances List Assessment Report - Inorganic Chloramines, DACO: 10.2.1 (published)

Additional Information Considered

Published Information

PMRA

Number

Reference

1422017

Health Canada, 2007, Guidelines for Canadian Drinking Water Quality -
Summary Table.